Neumedicines Inc. is a privately held, clinical stage, biotechnology company developing protein therapeutics that address unmet clinical and societal needs in the areas of Oncology, Infectious Disease, Hematology and Immunology.

NM-IL-12 (aka HemaMax™, and recombinant human interleukin-12 or rHuIL-12), the company’s lead product in development, targets multiple pathways of innate and adaptive immunity, as well as hematopoiesis, and is being developed to address a range of clinical indications.

At Neumedicines, we are committed to maximizing the scientific, clinical, and commercial potential of our product pipeline.